Clinical TrialID 7468
Topical SGX302 for Mild-to-Moderate Psoriasis
NCT05442190
Psoriasis|Plaque Psoriasis|Psoriasis Vulgaris
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7468
- Evidence Id
- 7468
- Core Evidence Id
- 7468
- Source Clinical Trial Id
- 7463
- Herb2 Clinical Trial Id
- HBCT007463
- Nct Id
- NCT05442190
- Title
- Topical SGX302 for Mild-to-Moderate Psoriasis
- Status
- Recruiting
- Phase
- Phase 2
- Study Result
- No
- Study Condition
- Psoriasis|Plaque Psoriasis|Psoriasis Vulgaris
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: Hypericin|DRUG: Placebo
- Intervention Allocation
- Randomized
- Intervention Model
- Sequential
- Intervention Mask
- Quadruple
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 42
- Outcome Measure
- Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scale, The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions, 18 weeks
- Sponsor Collaborator
- Soligenix
- Funded By
- INDUSTRY
- Location
- Therapeutics Clinical Research, San Diego, California, 92123, United States
- Other Id
- HPN-PSR-01
- Start Date
- 2022-12-14
- Primary Completion Date
- 2025-04
- Completion Date
- 2025-06
- First Posted
- 2022-07-01
- Results First Posted
- Last Update Posted
- 2024-04-24
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05442190
- Title Cn
- Title En
- Topical SGX302 for Mild-to-Moderate Psoriasis
- Bilingual Status
- semi_complete